Bispecific Antibody Takes Down FL.

In a pivotal phase I/II trial, the investigational bispecific T-cell engaging antibody mosunetuzumab demonstrated high response rates, significantly bettering those historically seen with standard care in patients with relapsed/refractory follicular lymphoma. Drug maker Genentech announced it will file for FDA approval of mosunetuzumab to treat this form of non-Hodgkin lymphoma.